Clinical Challenges and Predictive Risk Factors for Outcomes in COVID-19–Associated Mucormycosis
Rattachement africain : ir, es. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background & Objective: Mucormycosis has emerged as a severe complication in COVID-19 patients, particularly among those with uncontrolled diabetes and those receiving corticosteroid therapy. The infection's tendency to spread from the sinuses to the orbit and central nervous system (CNS) significantly increases morbidity and mortality. This study aimed to identify clinical risk factors and outcomes associated with disease severity and mortality in COVID-19–associated mucormycosis (CAM), with a focus on disease progression to orbital and CNS involvement.Methods: A total of 180 confirmed CAM patients were enrolled and classified into three groups based on disease extent: sinus-only, sinus with orbital involvement, and sinus with both orbital and CNS involvement. Data were collected on demographics, clinical history, laboratory findings, imaging results, treatment modalities, and outcomes.Results: Of the 180 patients, 63.3% had sinus-only involvement, 23.9% had sinus and orbital involvement, and 12.8% had sinus, orbital, and CNS involvement. Uncontrolled diabetes was observed in 38% of patients and was more prevalent in those with extensive disease. Corticosteroid use was significantly associated with disease severity (p = 0.002). Invasive procedures, such as orbital exenteration, were significantly linked to CNS progression (p < 0.05). The overall mortality rate was 31% (55 of 180 patients).Conclusion: Uncontrolled diabetes and corticosteroid therapy are major risk factors for severe CAM. Extension of mucormycosis beyond the sinuses, particularly to the orbit and CNS, is associated with poor clinical outcomes and often requires aggressive surgical management. Early diagnosis and prompt intervention are essential to improve survival in these patients.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Clinical Challenges and Predictive Risk Factors for Outcomes in COVID-19–Associated Mucormycosis
- Date Crossref
- 01/07/2025
- Éditeur
- Farname, Inc.
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Tehran University of Medical Sciences Research Center for Antibiotic Stewardship and Antimicrobial Resistance pays non établi dans la noticeUniversité ou école supérieure
-
Imam Khomeini Hospital pays non établi dans la noticeÉtablissement de santé
-
Instituto de Salud Carlos III pays non établi dans la noticeOrganisation à but non lucratif
-
Farabi Hospital pays non établi dans la noticeÉtablissement de santé
-
Mazandaran University of Medical Sciences pays non établi dans la noticeUniversité ou école supérieure
-
School of Public Health Department of Medical Parasitology and Mycology pays non établi dans la noticeUniversité ou école supérieure
-
Mycology Reference Laboratory pays non établi dans la noticeStructure de recherche
-
Faculty of Health Student Research Committee pays non établi dans la noticeUniversité ou école supérieure
Research Center for Antibiotic Stewardship and Antimicrobial Resistance — Tehran University of Medical Sciences, Imam Khomeini Hospital et Instituto de Salud Carlos III, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.